Translational Breast Cancer Research最新文献

{"title":"Current understandings and prospects of antibody-drug conjugates (ADCs) for the treatment of breast cancer: a narrative review","authors":"Chun-fang Hao, Hong Liu","doi":"10.21037/tbcr-21-30","DOIUrl":"https://doi.org/10.21037/tbcr-21-30","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128577522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pseudoangiomatous stromal hyperplasia causing massive unilateral breast enlargement—a case report","authors":"A. Brodie, A. Eltatawy, K. Lambert","doi":"10.21037/tbcr-21-37","DOIUrl":"https://doi.org/10.21037/tbcr-21-37","url":null,"abstract":"Pseudoangiomatous stromal hyperplasia (PASH) is an uncommon mesenchymal benign breast neoplasm (1). It was first studied by Vuitch et al. in 1986 in 9 patients who presented with palpable, grossly circumscribed, nonhaemorrhagic breast masses (2). On histological examination, the masses were composed of mammary s tromal proliferations with complex anastomosing channels lined with slender spindle cells stimulating vascular channels (3). Therefore, the histological appearance resembles, without constituting, an angiomatous proliferation (3). Vuitch et al. highlighted the importance of distinguishing this Case Report","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"603 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116209319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunities","authors":"A. Awada, A. Gombos","doi":"10.21037/tbcr-21-25","DOIUrl":"https://doi.org/10.21037/tbcr-21-25","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123671066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: rare breast tumor—Schwannoma of the breast","authors":"Leva Gorji, Erin K. O’Neill, A. Archer","doi":"10.21037/tbcr-21-17","DOIUrl":"https://doi.org/10.21037/tbcr-21-17","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115499985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients","authors":"Qing Wang, Dechun Yang, Jialin Mei, Sijia Li, Siqi Xie, Hengyu Zhang, Lanyi Dai, Ziyu Zhu, Yafeng Lv, Fuying Yang, Dequan Liu, R. Guo, Shicong Tang","doi":"10.21037/tbcr-21-34","DOIUrl":"https://doi.org/10.21037/tbcr-21-34","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116958330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More than 14 years’ progress free survival of neratinib monotherapy for human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer: a case report","authors":"Lina Zhang, Shaohua Zhang, Yang Yuan, Jianbin Li, Feng Li, C. Geng, Zefei Jiang","doi":"10.21037/tbcr-21-32","DOIUrl":"https://doi.org/10.21037/tbcr-21-32","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"100 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124126519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A narrative review of human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates in the treatment of breast cancer","authors":"Qun Li, Ye Guo, Fengjuan Lin, Lingjun Li, Xiaoxiao Ge, Wei Zhao, Jin Li","doi":"10.21037/tbcr-21-33","DOIUrl":"https://doi.org/10.21037/tbcr-21-33","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"106 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124671697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-detection remains a primary means of breast cancer detection in Beijing, China","authors":"Yuyan Yang, Junping Yu, Yizhou Bai, Anyang Liu, Jin-Yi Tian, Lijing Guo, Dongfang Huo, Peiliang Zhao, Wuyang Ji, Bin Luo","doi":"10.21037/tbcr-22-2","DOIUrl":"https://doi.org/10.21037/tbcr-22-2","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125188024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A fatal case of pneumonitis and hypogammaglobulinemia with use of a CDK4/6 inhibitor in metastatic breast cancer: case report","authors":"S. Ashraf, L. Biglow, Jennifer L. Dotson, M. Tirona","doi":"10.21037/tbcr-21-19","DOIUrl":"https://doi.org/10.21037/tbcr-21-19","url":null,"abstract":"","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129360619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monarch plus: a research review","authors":"T. Sun, Junnan Xu, Jun Yang","doi":"10.21037/tbcr-21-6","DOIUrl":"https://doi.org/10.21037/tbcr-21-6","url":null,"abstract":"According to the most recent approximations of the global burden of cancer by the International Agency for Research on Cancer (IARC), breast cancer has exceeded lung cancer as the most commonly diagnosed malignancy worldwide. In China, the number of new breast cancer cases is 272,400 annually, with 69,500 deaths (1). Approximately 70% of breast cancers are hormone receptor (HR)-positive, which has a favorable prognosis with hormone-dependent and novel targeted drugs synergistically combined with antiestrogens. Inhibitors of cyclin-dependent kinases 4 and 6 (CDK 4/6i) have been confirmed as the standard of treatment, combined with endocrine therapy (ET), in either the first-line setting or after progression on ET (2). Several large randomized studies have shown that the standard therapy of CDK4/6is (with three FDA-approved agents: palbociclib, abemaciclib, and ribociclib) combined with ET exhibits enormous anti-cancer activity, and is affordable and safe in HR-positive, human epidermal growth factor 2 (HER2)-negative advanced breast cancer (ABC) (3-7). At present, the National Medical Products Administration (NMPA) has approved two CDK4/6is, palbociclib and abemaciclib. According to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Diagnosis and Treatment Guidelines, 2021 updated version, the preferred treatment recommendation is CDK4/6is combined with ET in HR-positive and HER2-negative ABC. Also, abemaciclib combined with fulvestrant was highlighted as level 1A— evidence for treatment after progression on a previous aromatase inhibitor (AI), which was separated from level 2A—evidence of palbociclib combined with fulvestrant. Abemaciclib is a selective inhibitor of CDK4/6, and is the only CDK4/6i that may be given continuously and also be used as a monotherapy (8). In addition, abemaciclib seems to cross the blood-brain barrier, thereby activating the central nervous system (CNS) (9). Two large randomized studies (MONARCH3/2) (5,6) have shown that the progression-free survival (PFS) for abemaciclib combined with a non-steroidal AI or fulvestrant significantly improved in HR/HER2 ABC. Updated analyses have also demonstrated a marked improvement in overall survival (OS) with the combination of fulvestrant with abemaciclib. The recommendations of the CSCO 2021 guidelines were updated with a strong reference to the global MONARCH series clinical trials as well as a multinational, randomized, double-blind, placebo-controlled phase III trial— MONARCH plus (10). In this article, we review the key aspects of the MONARCH plus study.","PeriodicalId":344792,"journal":{"name":"Translational Breast Cancer Research","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116626736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}